1. 232 THE SIGNIFICANCE OF TRANSCRIPTION FACTORS FLI1 AND P53 FOR THE EFFECTIVE MEGAKARYOPOIESIS STUDIED IMMUNOHISTOCHEMICALLY IN 5Q- SYNDROME AND THE EFFECT OF LENALIDOMIDE TREATMENT. Issue 1 (April 2015) Authors: Campr, V.; Stritesky, J.; Neuwirtova, R.; Fuchs, O.; Jonasova, A. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Beyond rituximab maintenance. relapsing follicular lymphoma during or after end of rituximab maintenance: analysis of Czech Lymphoma Study Group (CLSG) database. (June 2017) Authors: Janikova, A.; Campr, V.; Kopalova, N.; Benesova, K.; Belada, D.; Prochazka, V.; Duras, J.; Dlouha, J.; Mocikova, H.; Sykorova, A.; Brejcha, M.; Mayer, J.; Trneny, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Burkitt lymphoma–multicenter retrospective data analysis from the Czech Lymphoma Study Group–NiHiL project. (June 2017) Authors: Sýkorová, A.; Pytlík, R.; Móciková, H.; Janíková, A.; Procházka, V.; Belada, D.; Šálek, D.; Benešová, K.; Klener, P.; Ďuraš, J.; Smolej, L.; Šimkovič, M.; Campr, V.; Vosáhlová, V.; Blahovcová, P.; Trněný, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 342 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOUBLE‐EXPRESSOR LYMPHOMAS DO NOT HAVE INFERIOR OUTCOME AFTER AUTOLOGOUS STEM‐CELL TRANSPLANT IN THE FIRST LINE TREATMENT. (June 2017) Authors: Trneny, M.; Campr, V.; Pytlik, R.; Klener, P.; Stritesky, J.; Jaksa, R.; Boudova, L.; Benesova, K.; Koren, J.; Trnkova, M.; Blahovcova, P.; Klanova, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. INCIDENCE AND OUTCOME OF PRIMARY EXTRANODAL FOLLICULAR LYMPHOMAS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY. (June 2017) Authors: Janikova, A.; Campr, V.; Kopalova, N.; Benesova, K.; Belada, D.; Dlouha, J.; Duras, J.; Prochazka, V.; Mocikova, H.; Kubackova, K.; Sykorova, A.; Brejcha, M.; Mayer, J.; Trneny, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY?. (12th June 2019) Authors: Trneny, M.; Polgarova, K.; Janikova, A.; Belada, D.; Prochazka, V.; Duras, J.; Mocikova, H.; Steinerova, K.; Campr, V.; Blahovcova, P.; Petrova, M.; Zogala, D.; Ptacnik, V. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. MAINTENANCE RITUXIMAB IMPROVES SURVIVAL IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP. (June 2017) Authors: Obr, A.; Klener, P.; Belada, D.; Pytlik, R.; Simkovic, M.; Salek, D.; Mocikova, H.; Prochazka, V.; Janikova, A.; Markova, J.; Campr, V.; Kodet, R.; Trneny, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE. (12th June 2019) Authors: Janikova, A.; Chloupkova, R.; Campr, V.; Kopalova, N.; Klener, P.; Benesova, K.; Hamouzova, J.; Belada, D.; Sykorova, A.; Prochazka, V.; Pirnos, J.; Duras, J.; Mocikova, H.; Michalka, J.; Trneny, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. RITUXIMAB MAINTENANCE AFTER NORDIC PROTOCOL (R‐MAXICHOP/HD‐ARAC/ASCT) SIGNIFICANTLY PROLONGS SURVIVAL IN YOUNG MANTLE CELL LYMPHOMA PATIENTS. (June 2017) Authors: Klener, P.; Salek, D.; Mocikova, H.; Blahovcova, P.; Pytlik, R.; Janikova, A.; Prochazka, V.; Campr, V.; Boudova, L.; Jaksa, R.; Kodet, R.; Trneny, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 206 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. R‐CHOP/R‐HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS. (June 2017) Authors: Klener, P.; Fronkova, E.; Belada, D.; Forsterova, K.; Pytlik, R.; Kalinova, M.; Simkovic, M.; Salek, D.; Mocikova, H.; Prochazka, V.; Blahovcová, P.; Janikova, A.; Markova, J.; Obr, A.; Berkova, A.; Vaskova, M.; Mejstrikova, E.; Campr, V.; Kubinyi, J.; Jaksa, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗